AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16682727 — intervention group
Group type: COMPARATOR
Intervention: Intravenous docetaxel 75 mg/m2 day 1 every 21 days
Number of subjects: 829
Study 16281645 — intervention group
Group type: EXPERIMENTAL
Intervention: Care plan
Number of subjects: 92
Study 16281645 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 92
Study 10469815 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV plus ddI combination therapy
Number of subjects: 831
Study 10469815 — intervention group
Group type: COMPARATOR
Intervention: ZDV monotherapy
Number of subjects: 831
Study 10469815 — intervention group
Group type: COMPARATOR
Intervention: ddI monotherapy
Number of subjects: 831
Study 8915214 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered Wallstent
Number of subjects: 40
Study 1856814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine
Number of subjects: 12
Study 1856814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6849160 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram 400 mg/d
Number of subjects: 0
Study 6849160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31829248 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol administration for three days during the perioperative period
Number of subjects: 400
Study 31829248 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 400
Study 29289374 — intervention group
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg qhs
Number of subjects: 111
Study 29289374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 27754700 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-MLR (Methylphenidate HCl Extended-Release)
Number of subjects: 256
Study 23786900 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic food
Number of subjects: 62
Study 21070566 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal manual repair (group 1)
Number of subjects: 45
Study 21070566 — intervention group
Group type: COMPARATOR
Intervention: Transanal stapled repair (group 2)
Number of subjects: 45
Study 20537810 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual cessation with nicotine lozenge (via mail)
Number of subjects: 746
Study 20537810 — intervention group
Group type: COMPARATOR
Intervention: Abrupt cessation
Number of subjects: 746
Study 20537810 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment
Number of subjects: 746
Study 18546662 — intervention group
Group type: EXPERIMENTAL
Intervention: Checkerboard with alternated dark and light shapes superimposed on the corners of the squares
Number of subjects: 0
Study 18546662 — intervention group
Group type: EXPERIMENTAL
Intervention: Theories of boundary completion and edge propagation
Number of subjects: 0
Study 18546662 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions sensitive to contrast sign
Number of subjects: 0
Study 18546662 — intervention group
Group type: EXPERIMENTAL
Intervention: Café Wall illusion hypothesis
Number of subjects: 0
Study 15940624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (peginterferon and lamivudine)
Number of subjects: 47
Study 15940624 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 47
Study 15940624 — intervention group
Group type: EXPERIMENTAL
Intervention: Log intrahepatic cccDNA
Number of subjects: 47
Study 15940624 — intervention group
Group type: EXPERIMENTAL
Intervention: Log intrahepatic HBV DNA
Number of subjects: 47
Study 15940624 — intervention group
Group type: EXPERIMENTAL
Intervention: Log cccDNA at -0.80 copies/genome equivalent
Number of subjects: 47
Study 12900381 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol (1 microM)
Number of subjects: 8
Study 12900381 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (10 microM)
Number of subjects: 8
Study 12900381 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (10 microM) with phentolamine (100 microM)
Number of subjects: 8
Study 10100770 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily 0.75% metronidazole gel 5 g intravaginally for 5 days
Number of subjects: 514
Study 10100770 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily 0.75% metronidazole gel 5 g intravaginally for 5 days
Number of subjects: 514
Study 9050699 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen and progesterone postoperatively
Number of subjects: 50
Study 9050699 — intervention group
Group type: COMPARATOR
Intervention: No hormone (control group)
Number of subjects: 50
Study 1880221 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg BID to a maximum of 400 mg BID over 6 weeks)
Number of subjects: 112
Study 1880221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 1880221 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg or less BID)
Number of subjects: 112
Study 1880221 — intervention group
Group type: COMPARATOR
Intervention: Labetalol and Placebo
Number of subjects: 112
Study 6605127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicaval venous drainage without snaring and left ventricular venting through the superior pulmonary vein
Number of subjects: 60
Study 6605127 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐stage venous drainage and venting as in Group 1
Number of subjects: 60
Study 6605127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicaval venous drainage without snaring and no left ventricular vent
Number of subjects: 60
Study 6605127 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐stage venous drainage and no left ventricular vent
Number of subjects: 60
Study 6605127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicaval venous drainage without snaring and with ascending aortic venting through a catheter
Number of subjects: 60
Study 6605127 — intervention group
Group type: EXPERIMENTAL
Intervention: Two‐stage venous drainage and venting as in Group 5
Number of subjects: 60
Study 30909779 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive self-statements
Number of subjects: 0
Study 30909779 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-nodding condition
Number of subjects: 0
Study 30909779 — intervention group
Group type: COMPARATOR
Intervention: Head-shaking condition
Number of subjects: 0
Study 29162142 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent thermochemoradiotherapy (HTCTRT) with locoregional hyperthermia (weekly ×6 during radiotherapy) and concurrent chemoradiotherapy (CTRT) with gemcitabine (400 mg/m2, weekly ×6)
Number of subjects: 86
Study 29162142 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiotherapy (CTRT) alone with gemcitabine (400 mg/m2, weekly ×6)
Number of subjects: 86
Study 27379509 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (40 mg, IV)
Number of subjects: 65
Study 27379509 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, IV)
Number of subjects: 65
Study 24703945 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional palliative care intervention program
Number of subjects: 859
Study 22818725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried apple (75 g/day)
Number of subjects: 160
Study 22818725 — intervention group
Group type: COMPARATOR
Intervention: Dried plum (comparative control)
Number of subjects: 160
Study 22818725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried apple and dried plum
Number of subjects: 160
Study 20118174 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (n = 2220)
Number of subjects: 4447
Study 20118174 — intervention group
Group type: COMPARATOR
Intervention: Combination of metformin and sulfonylurea (n = 2227)
Number of subjects: 4447
Study 18343266 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg
Number of subjects: 100
Study 18343266 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 100
Study 18343266 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil 50 mg
Number of subjects: 100
Study 18343266 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 15911461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 678
Study 15911461 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 678
Study 15911461 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene plus Metformin
Number of subjects: 678
Study 12583464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide and lipid peroxides plasma concentrations; superoxide dismutase activity in RBC membranes
Number of subjects: 0
Study 10508816 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for peer groups of doctors
Number of subjects: 0
Study 8478821 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic therapy
Number of subjects: 24
Study 8478821 — intervention group
Group type: COMPARATOR
Intervention: Supportive group psychotherapy
Number of subjects: 24
Study 3102275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 2 mg
Number of subjects: 9
Study 3102275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 10 mg
Number of subjects: 9
Study 3102275 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 20 mg
Number of subjects: 9
Study 3102275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29426792 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted TKA (group NAV)
Number of subjects: 200
Study 29426792 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA (group CONV)
Number of subjects: 200
Study 29426792 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study 26970415 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD-Q questionnaire
Number of subjects: 403
Study 26187711 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase (low estradiol and progesterone)
Number of subjects: 40
Study 26187711 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase (higher estradiol and progesterone)
Number of subjects: 40
Study 26187711 — intervention group
Group type: COMPARATOR
Intervention: Control condition (before TSST)
Number of subjects: 40
Study 26187711 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 40
Study 24219416 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived racial discrimination
Number of subjects: 130
Study 24219416 — intervention group
Group type: EXPERIMENTAL
Intervention: Mistrust of medical researchers
Number of subjects: 130
Study 24219416 — intervention group
Group type: COMPARATOR
Intervention: Heat pain sensitivity
Number of subjects: 130
Study 21631478 — intervention group
Group type: EXPERIMENTAL
Intervention: Telcagepant 300 mg
Number of subjects: 28
Study 21631478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18947029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine-fortified wheat flour
Number of subjects: 106
Study 16864832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihemispheric motor network reorganization
Number of subjects: 10
Study 12616672 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (250.0 mg/day for 14 days)
Number of subjects: 12
Study 10704631 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma from patients with 83+/‐4% stenosis
Number of subjects: 105
Study 10704631 — intervention group
Group type: COMPARATOR
Intervention: Plasma from controls with added synthetic oxysterols
Number of subjects: 105
Study 9794089 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium orotate 3 x 1 g
Number of subjects: 14
Study 9794089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7834732 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipurpose‐SM catheter
Number of subjects: 84
Study 7834732 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 3137607 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 10
Study 3137607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31786126 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0
Study 31786126 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependence
Number of subjects: 0
Study 31786126 — intervention group
Group type: COMPARATOR
Intervention: γ‐glutamyltransferase levels
Number of subjects: 0
Study 31786126 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption, alcohol dependence, AUDIT scores
Number of subjects: 0
Study 28436694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 211
Study 28436694 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 211
Study 27503262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative computed tomography (CT) scan assisted-navigation
Number of subjects: 114
Study 27503262 — intervention group
Group type: COMPARATOR
Intervention: Free-hand fluoroscopy-guided surgery
Number of subjects: 114
Study 26119654 — intervention group
Group type: EXPERIMENTAL
Intervention: On-statin resistin levels
Number of subjects: 352
Study 26119654 — intervention group
Group type: EXPERIMENTAL
Intervention: On-statin leptin levels
Number of subjects: 352
Study 23924165 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical decompression (within 24 hours after admission)
Number of subjects: 100
Study 23924165 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery (later than two weeks)
Number of subjects: 100
Study 21099129 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide treatment for 3 months before surgery
Number of subjects: 39
Study 21099129 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting octreotide treatment
Number of subjects: 39
Study 21099129 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery directly)
Number of subjects: 39
Study 18262147 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg of vaginal misoprostol
Number of subjects: 120
Study 18262147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 16700996 — intervention group
Group type: EXPERIMENTAL
Intervention: Head hypothermia treatment
Number of subjects: 124
Study 16700996 — intervention group
Group type: COMPARATOR
Intervention: Control group (no head hypothermia)
Number of subjects: 124
Study 12974974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held echocardiography (HHE)
Number of subjects: 103
Study 12974974 — intervention group
Group type: COMPARATOR
Intervention: Conventional transthoracic echocardiography (TTE)
Number of subjects: 103
Study 11250719 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing hormone-releasing hormone (LHRH) agonists with low-dose hormone replacement
Number of subjects: 0
Study 8666622 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger packing
Number of subjects: 30
Study 8666622 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde gun cementing
Number of subjects: 30
Study 1403273 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone
Number of subjects: 60
Study 1403273 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 60
Study 30824830 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBI training (experimental group)
Number of subjects: 44
Study 30824830 — intervention group
Group type: COMPARATOR
Intervention: Classical training (control group)
Number of subjects: 44
Study 29485324 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Supplement (PRO, 42 g/serving)
Number of subjects: 51
Study 27243611 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily music training for 28 days
Number of subjects: 0
Study 27243611 — intervention group
Group type: COMPARATOR
Intervention: French language training for 28 days
Number of subjects: 0
Study 27243611 — intervention group
Group type: COMPARATOR
Intervention: Both training types
Number of subjects: 0
Study 23291502 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin Block (TB)
Number of subjects: 103
Study 23291502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamax (Dx)
Number of subjects: 103
Study 22288685 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-dose hydrocortisone regimen (10 + 10 + 5 + 5 mg)
Number of subjects: 15
Study 22288685 — intervention group
Group type: COMPARATOR
Intervention: Two-dose hydrocortisone regimen (20 + 0 + 10 + 0 mg)
Number of subjects: 15
Study 19815044 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood enhancement (comedy movie clip)
Number of subjects: 106
Study 19815044 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 106
Study 18478944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil at 0.3 ng/ml with nitrogen monoxide inhalation at 0.9 MAC
Number of subjects: 60
Study 18478944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil at 0.4 ng/ml with nitrogen monoxide inhalation at 0.9 MAC
Number of subjects: 60
Study 18478944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil at 0.5 ng/ml with nitrogen monoxide inhalation at 0.9 MAC
Number of subjects: 60
Study 15560968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.6 mg/kg/h)
Number of subjects: 16
Study 15560968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study 12084590 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT)
Number of subjects: 749
Study 12084590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study 9930787 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrobar
Number of subjects: 56
Study 9930787 — intervention group
Group type: COMPARATOR
Intervention: E-Z-Paque
Number of subjects: 56
Study 8524979 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) at doses of 1.5 micrograms/kg and 2.5 micrograms/kg
Number of subjects: 0
Study 8524979 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZP) at doses of 5 mg and 10 mg
Number of subjects: 0
Study 2405171 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (total mean dose of 54 Gy to the breast)
Number of subjects: 381
Study 2405171 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (no further treatment)
Number of subjects: 381
Study 2405171 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 381
Study 2405171 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 381
Study 415321 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (0.7 mg/kg delta‐9‐tetrahydrocannabinol)
Number of subjects: 12
Study 415321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (1.0 ml/kg 95% ethanol)
Number of subjects: 12
Study 415321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31638330 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT measurements in patients with normal baseline hsTnT values (N = 357)
Number of subjects: 530
Study 31638330 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT measurements in patients with elevated baseline hsTnT values (N = 173)
Number of subjects: 530
Study 30165156 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% reduction of basal insulin applied 40 minutes before exercise (T-40)
Number of subjects: 22
Study 30165156 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% reduction of basal insulin applied 20 minutes before exercise (T-20)
Number of subjects: 22
Study 30165156 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% reduction of basal insulin applied at exercise onset (T0)
Number of subjects: 22
Study 28931236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) with primaquine (PQ)
Number of subjects: 0
Study 28931236 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 0
Study 25766513 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Number of subjects: 66
Study 23466100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 73
Study 23466100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 73
Study 23466100 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg and 40 mg
Number of subjects: 73
Study 23466100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 21771987 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus triptorelin (3.75 mg intramuscularly at least 1 week before chemotherapy and then every 4 weeks during chemotherapy)
Number of subjects: 281
Study 21771987 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 281
Study 19002689 — intervention group
Group type: EXPERIMENTAL
Intervention: Studer pouch
Number of subjects: 462
Study 19002689 — intervention group
Group type: COMPARATOR
Intervention: T-pouch
Number of subjects: 462
Study 16766776 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (12 g of BCAAs/day; leucine 54%, isoleucine 19%, valine 27%)
Number of subjects: 19
Study 16766776 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 g of glucose/day)
Number of subjects: 19
Study 15634480 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK surgery with residual corneal stroma bed thickness
Number of subjects: 227
Study 15634480 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK surgery with residual corneal stroma bed thickness > 300 microm
Number of subjects: 227
Study 15634480 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative measurement of posterior curvature of cornea
Number of subjects: 227
Study 10760641 — intervention group
Group type: EXPERIMENTAL
Intervention: UK IBDQ
Number of subjects: 180
Study 9250944 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine psychedelic therapy (KPT)
Number of subjects: 211
Study 9250944 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 211
Study 8222534 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion (20-30 ng kg-1 min)
Number of subjects: 20
Study 8222534 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 3929876 — intervention group
Group type: EXPERIMENTAL
Intervention: Feverfew capsules (freeze dried powder)
Number of subjects: 17